Concepedia

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

Antoine Adenis, Christelle de la Fouchardière, Bernard Paule, Pascal Burtin, David Tougeron, Jennifer Wallet, Louis-Marie Dourthe, Pierre-Luc Etienne, Laurent Mineur, Stéphanie Clisant,

BMC Cancer · 2016 · 126 citations · 6 references

DOIFull text

Open access

Abstract

Clinicaltrials.gov NCT02310477 .

References

6

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Axel Grothey, Eric Van Cutsem, Alberto Sobrero et al. · The Lancet · 2012 · 2.8K citations

, , +9

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

Jin Li, Shukui Qin, Rui‐Hua Xu et al. · The Lancet Oncology · 2015 · 791 citations

, , +8

A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

K. Mross, Annette Frost, Simone Steinbild et al. · Clinical Cancer Research · 2012 · 329 citations

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

Josep Tabernero, Heinz‐Josef Lenz, Salvatore Siena et al. · The Lancet Oncology · 2015 · 324 citations · Full text

, , +11

140O Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC)

Eric Van Cutsem, Fortunato Ciardiello, Jean‐François Seitz et al. · Annals of Oncology · 2015 · 20 citations · Full text

, , +9